AstraZeneca resumes coronavirus vaccine trials in the UK

The Medicines Health Regulatory Authority has advised it was safe to restart the tests

AstraZeneca - AstraZeneca resumes COVID-19 vaccine trials in the UK

AstraZeneca PLC (LON:AZN) announced over the weekend that clinical trials for the coronavirus (COVID-19) vaccine under development by Oxford University have resumed in the UK.

Global tests, carried out in the UK, US, South Africa, England, Russia and Brazil, paused last week after a participant in the UK registered adverse effects.

READ: AstraZeneca to move to Nasdaq from New York Stock Exchange

But the FTSE 100-listed group said they are now underway again in the UK after the Medicines Health Regulatory Authority advised that it was safe to do so.

Oxford University Professor Andrew Pollard said in August that data could be put before regulators as early as this year. but ensuring safety and efficacy is paramount.

AstraZeneca has sourced capacity for 2bn doses.

Quick facts: AstraZeneca

Price: 8605 GBX

Market: LSE
Market Cap: £112.86 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


MBH Corporation's Callum Laing highlights four crucial investment trends

In the next four videos MBH Corporation Plc's (FRA:M8H) Callum Laing looks at four major historical investment trends and how understanding them can give clues as to what may be coming next. He says each of them are now beginning to compound upon each other and offers investors a unique...

58 minutes ago

2 min read